Postoperative adjuvant radiotherapy improves the survival of HPV16 negative esophageal squamous cell carcinoma at stageⅡa / 术后辅助放疗可提高HPV16阴性Ⅱa期食管鳞癌患者根治术后的生存率

• Published in: Xi'an jiao tong da xue xue bao. Journal of Xi'an Jiaotong University (medical sciences). Yi xue ban no. 6; p. 857
• Main Authors: ZHANG, Li, Ru-xing, XI, Zhang-jun, SONG, Shao-min, CHE, Xiao-zhi, ZHANG
• Format: Journal Article
• Language: Chinese
• Published: Xi'an Xi'an Jiaotong University 01.01.2016
• Subjects: Esophageal cancer; Esophagus; Medical prognosis; Radiation therapy; Squamous cell carcinoma
• ISSN: 1671-8259
• DOI: 10.7652/jdyxb201606017

Objective: To explore the prognostic factors and significance of postoperative adjuvant radiotherapy for HPV16-associated esophageal squamous cell carcinoma (ESCC) patients at UICC stage Ⅱa. Methods: Pathological specimens of 97 patients with ESCC at stage IIa and esophageal mucosa or paracancerous tissues of 54 normal subjects in the First Affiliated Hospital of Xi’an Jiaotong University from January 2007 to September 2009 were retrospectively analyzed for the expressions of HPV16E6, p75NTR and PI3K using immunohistochemistry, their correlation with the patients’ clinical characteristics and prognosis, as well as the impact of postoperative adjuvant radiotherapy on the survival rate of patients with ESCC at stage Ⅱa. Results: The expression of HPV E6 was 64.9% in ESCC. The 5-year overall survival rates was 42.3%, and the median was 52 months. The 5-year survival rates of HPV16 negative and HPV16 positive were 67.6% and 25.3%, respectively (P<0.001). The 5-year survival rates of adjuvant radiotherapy and non-